ImmunityBio Announces Authorization to Proceed with Phase I/II/III Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

ImmunityBio, Inc. announced authorization from the South Africa Health Products Regulatory Authority to proceed with the South Africa Sisonke T-Cell Universal Boost trial. The Phase I/II/III study, which will begin in Q3 2021, is designed to evaluate hAd5 Spike + Nucleocapsid as a boost for South African healthcare workers previously vaccinated with an S-only vaccine.